To further determine whether activity of the CHK1 pathway plays a role in the synergistic antitumor interactions between panobinostat and the standard chemotherapeutic drugs in high-risk neuroblastoma cells, we used a CHK1-specific inhibitor, LY2603618 [31]. This evidence concerns the gene CHEK1 and neuroblastoma.